Citigroup says AstraZeneca's (AZN) additional three weeks of data on AZD9291 shows less potency, more rash/diarrhea and no dose response for AZD9291. Citi believes the data shows that the AstraZeneca drug is not "CO-1686 killer that investors were worried about." Clovis (CLVS) makes CO-1686. Citi still thinks the lung cancer market is big enough for both drugs and keeps a Buy rating on Clovis with a $109 price target.
- Health Care Industry